Importantly, rFGF1 administration inhibited cardiac hypertrophy and fibrosis in TAC- or Ang II-induced models and enhanced OXPHOS by activating PGC1α/β. The gene discussed is PPARGC1A; the disease is cardiac hypertrophy.